Skip to contentA
Agios Pharmaceuticals, Inc.
A
AGIOAgios Pharmaceuticals, Inc. Q1 2026 · 10-Q
Revenue$20.75M$20.75M+137.7% vs Q1 2025 Net Income-$99.11M-$99.11MN/M vs Q1 2025 EPS Diluted-$1.69-$1.69N/M vs Q1 2025 Operating Income-$110,025,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Agios Pharmaceuticals, Inc. · CIK 1439222 · Engraved from SEC EDGAR
Free Cash Flowderived-$119,689,000N/M Margins · derivedOperating margin-530.3%+691.6 pt vs Q1 2025
Net margin-477.7%+545.5 pt vs Q1 2025
ended Mar 31, 2026 · filed Apr 29, 2026 · 29 d after period end